Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.36 |
| ▸ | RELA | Q04206 | 4/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4030322 | 1.00 | CA1 (0.39) | CA1CA2CA7GAAEPHX2 | |
| SCHEMBL19194733 | 0.84 | CA1 (0.38) | CA1CA2CA7GAAEPHX2 | |
| SCHEMBL8467956 | 0.80 | TSHR (0.36) | CA1CA2EPHX2TSHR | |
| SCHEMBL2001628 | 0.80 | CA1 (0.44) | CA1CA2CA7GAACYP2D6 | |
| SCHEMBL17494216 | 0.80 | TSHR (0.36) | CA1CA2EPHX2TSHR | |
| SCHEMBL8467430 | 0.78 | SCN8A (0.33) | TSHR | |
| SCHEMBL24439605 | 0.77 | CA1 (0.47) | CA1CA2CA7EPHX2CYP2D6 | |
| SCHEMBL25281173 | 0.77 | CA1 (0.47) | CA1CA2CA7EPHX2CYP2D6 | |
| SCHEMBL7502948 | 0.76 | CACNA1B (0.32) | CA1CA2CA7GAAEPHX2 | |
| SCHEMBL3188762 | 0.75 | CA1 (0.40) | CA1CA2CA7CYP2D6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1015445-B1 | ANTIMICROBIAL QUINOLONES, THEIR COMPOSITIONS AND USES | PROCTER & GAMBLE (US) | 2009-02-25 | — | — | EP | disclosed |
| US-7482454-B2 | Antimicrobial quinolones, their compositions, and uses | THE PROCTER & GAMBLE COMPANY (US) | 2009-01-27 | — | — | US | disclosed |
| US-20060100436-A1 | Antimicrobial quinolones, their compositions, and uses | WARNER CHILCOTT COMPANY, LLC | 2006-05-11 | — | — | US | disclosed |
| US-6329391-B1 | ANTIBIOTICS, BACTERICIDES USING QUINOLONES | THE PROCTER & GAMBLE CO. | 2001-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100436-A1 | Antimicrobial quinolones, their compositions, and uses | Q6ZSR9, RECQL, QARS1 | CA1 4777/4885CA2 3059/4885CA7 3078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.